During the past decade, Royal Victorian Eye and Ear Hospital conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 9 clinical trials were completed, i.e. on average, 56.3% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 8 clinical trials were completed. i.e. 266.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Royal Victorian Eye and Ear Hospital" #1 sponsor was "Cochlear" with 5 trials, followed by "Hoffmann-La Roche" with 4 trials sponsored, "JHSPH Center for Clinical Trials" with 2 trials sponsored, "Apellis Pharmaceuticals, Inc." with 1 trials sponsored and "Bausch & Lomb Incorporated" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Royal Victorian Eye and Ear Hospital" #1 collaborator was "Royal Victoria Eye and Ear Hospital" with 4 trials as a collaborator, "National Eye Institute (NEI)" with 3 trials as a collaborator, "The Hearing Cooperative Research Centre" with 2 trials as a collaborator, "Aravind Eye Hospitals, India" with 1 trials as a collaborator and "Asociación para Evitar la Ceguera en México" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Royal Victorian Eye and Ear Hospital" are "Geographic Atrophy" (7 trials), "Macular Edema" (3 trials), "Uveitis" (3 trials), "Hearing Loss" (2 trials) and "Age Related Macular Degeneration" (1 trials). Many other conditions were trialed in "Royal Victorian Eye and Ear Hospital" in a lesser frequency.

Most popular intervention types in "Royal Victorian Eye and Ear Hospital" are "Drug" (11 trials), "Device" (6 trials), "Other" (4 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Lampalizumab" (2 trials), "No intervention" (2 trials), "ACE stimulation strategy" (1 trials), "CI632" (1 trials) and "CI632D" (1 trials). Other intervention names were less common.

The vast majority of trials in "Royal Victorian Eye and Ear Hospital" are 19 trials for "All" genders.

Currently, there are NaN active trials in "Royal Victorian Eye and Ear Hospital". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Royal Victorian Eye and Ear Hospital, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Royal Victorian Eye and Ear Hospital, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 6 trials that are defined as “Not Applicable".